Back Login to subscribe 🔔 Set Alert

QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares

15 min delay

Loading...

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	12 Health Care Stocks Moving In Monday's Pre-Market Session	95.26%
	Quantum Biopharma shares are trading higher after the company announced it received FDA approval to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis.	94.96%
	Quantum BioPharma Says FDA Cleared IND For Lucid-MS Phase 2 Trial In Progressive Multiple Sclerosis; Reports Cash Runway To At Least October 2027	80.94%
	EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial	55.71%
	EXCLUSIVE: FDA Approves Quantum BioPharma's Lucid-MS Phase 2 Trial of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination For Progressive Multiple Sclerosis	86.33%